Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G F Fleming

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorinG F Fleming, S M O'Brien, P C Hoffman, et al.
Cancer Chemotherapy and Pharmacology|April 1, 1999
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 daysM D DeMario, M J Ratain, N J Vogelzang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
A phase I study of sirolimus and bevacizumab in patients with advanced malignanciesE E W Cohen, M R Sharma, L Janisch, et al.
Journal of the National Cancer Institute|March 2, 1994
Phase I study of adozelesin administered by 24-hour continuous intravenous infusionG F Fleming, M J Ratain, S M O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancerG F Fleming, J W Kugler, P C Hoffman, et al.
Gynecologic Oncology|December 6, 2011
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaH J Mackay, R J Buckanovich, H Hirte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group studyG F Fleming, J M Fowler, S E Waggoner, et al.
Breast Cancer Research and Treatment|June 11, 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participantsAnn H Partridge, A C Wolff, P K Marcom, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorinG F Fleming, S M O'Brien, P C Hoffman, et al.
Cancer Chemotherapy and Pharmacology|April 1, 1999
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 daysM D DeMario, M J Ratain, N J Vogelzang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
A phase I study of sirolimus and bevacizumab in patients with advanced malignanciesE E W Cohen, M R Sharma, L Janisch, et al.
Journal of the National Cancer Institute|March 2, 1994
Phase I study of adozelesin administered by 24-hour continuous intravenous infusionG F Fleming, M J Ratain, S M O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancerG F Fleming, J W Kugler, P C Hoffman, et al.
Gynecologic Oncology|December 6, 2011
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaH J Mackay, R J Buckanovich, H Hirte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group studyG F Fleming, J M Fowler, S E Waggoner, et al.
Breast Cancer Research and Treatment|June 11, 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participantsAnn H Partridge, A C Wolff, P K Marcom, et al.
Pageof 6